Becton Dickinson | StockChase
30
Becton Dickinson (BDX-N)

Last Price Recorded: $224.2300 on 2017-11-23

ON STOCKCHASE SINCE May 2003

disposable medical supplies

biotechnology/pharmaceutical

Becton Dickinson


Signal Opinion Expert

2017-11-07

TOP PICK
Becton Dickinson (BDX-N)

A healthcare name in devices. They have the Bard C R (BCR-N) acquisition that should close before the end of the year, which will give them a mid-single digit accretion and nice cost synergies. They are in the devices space, where capital spending worldwide is strong and growing. They are good about using dividends to return capital to shareholders. Dividend yield of 1.3%. (Analysts' price target is $234.50.)

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Management

Price: $221.270
Owned: Yes

2017-10-16

COMMENT
Becton Dickinson (BDX-N)

Recently started buying this. For lack of a better way to describe it, this is like a full complete service provider for medical supplies to hospitals and clinics. They sell consumables such as syringes and catheters, and are trying to get more into drug delivery and software. Acquiring Bard C R (BCR-N). A great company and a good business to be in.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Management

Price: $200.820
Owned: Yes

2017-09-14

HOLD
Becton Dickinson (BDX-N)

He reduced some of his med-tech in January.  Almost every type of object that is used in the medical world is in their catalogue.  He wants to see how their acquisitions work out.  It is on his radar, but you are probably okay to hold it right now.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group

Price: $197.600
Owned: No

2017-08-29

TOP PICK
Becton Dickinson (BDX-N)

Acquiring Bard C R Inc., and is essentially going to be a one stop shop for hospitals, providing the product, providing analytics, providing administration. They get 58% of revenue from the US, so there is a big opportunity in emerging markets. He sees 5% revenue growth for many years to come. Sees them reducing debt in the next 2-3 years, and maybe making another material acquisition. Dividend yield of 1.4%. (Analysts’ price target is $216.50.)

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Management

Price: $198.900
Owned: Yes

2017-05-19

TOP PICK
Becton Dickinson (BDX-N)

This started a long time ago making syringes and needles, and that’s pretty much been their core. It’s all consumables in the hospitals, etc. Just made a recent acquisition of CR Bard (BCR-N) in the urology business. Both companies generate consistently growing free cash flows. There’s a 10% bump to the dividend every year. This merger is going to give them some debt that should be paid off within the next 2 years. He likes the company at this price.

biotechnology/pharmaceutical
David Driscoll

President & CEO, Liberty International Investment Management Inc

Price: $184.130
Owned: Yes

2011-11-21

PAST TOP PICK
Becton Dickinson (BDX-N)
(A Top Pick Aug 12/11. Down 8.41%.) Still likes. 38 consecutive years of dividend increases.
biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Management

Price: $71.840
Owned: Yes

2011-11-02

BUY on WEAKNESS
Becton Dickinson (BDX-N)
Disappointed earnings today so will be down tomorrow. Good dividend yield and trades at about 12X earnings. This is one you buy on weakness and average down. Good demographics.
biotechnology/pharmaceutical
John O'Connell, CFA

Chairman and CEO, Davis Rea

Price: $72.600
Owned: No

2011-08-12

TOP PICK
Becton Dickinson (BDX-N)
Medical technology. 38 years of consecutive dividend increases. Conservative payout ratio of 28%. 3 segments, medical, diagnostics and biosciences. All 3 have been growing at about 4%-5%. Met or exceeded earnings expectations for the last 5 years, usually 5%.
biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Management

Price: $80.280
Owned: Yes

2011-01-20

PAST TOP PICK
Becton Dickinson (BDX-N)
(A Top Pick Dec 31/09. Up 7.42%.)
biotechnology/pharmaceutical
Laura Wallace

Managing Director, Coleford Investment Management

Price: $83.090
Owned: Unknown

2010-07-14

BUY
Becton Dickinson (BDX-N)
Diagnostics is probably a good area to consider.
biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $69.590
Owned: Unknown

2010-05-13

TOP PICK
Becton Dickinson (BDX-N)
Medical devices. Selling into emerging markets where per capita spent on health care is very small. Generates a lot of free cash flow. Raised dividends over the last 37 years. Grown revenues from 2000 at 8% per year. Debt to cash flow is under 1X. Very stable business.
biotechnology/pharmaceutical
Michael Simpson, CFA

Senior Vice-President, Sentry Investments

Price: $74.470
Owned: Yes

2009-12-31

TOP PICK
Becton Dickinson (BDX-N)
Hospital supply company in the US and will benefit when 40-50 million more people are covered under a healthcare plan. Trading at 13.5X earnings. Great growth record.
biotechnology/pharmaceutical
Laura Wallace

Managing Director, Coleford Investment Management

Price: $78.860
Owned: Yes

2009-12-15

TOP PICK
Becton Dickinson (BDX-N)
So shareholder friendly in all the actions they have taken. Dividends rising for 36 years in a row. No debt, buying back shares. Modest growth, likes sector and dividend, which grows.
biotechnology/pharmaceutical
Ara Nalbandian

Portfolio Manager, Highwater Capital Management

Price: $77.650
Owned: Yes

2009-07-08

BUY
Becton Dickinson (BDX-N)
Manufactures medical devices. Looking for it to earn about $5.50 next year. Very steady, highly predictable.
biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $68.670
Owned: Unknown

2009-03-31

BUY
Becton Dickinson (BDX-N)
Just recently purchased this. Has good revision and good valuation in the healthcare space. Products include syringes, monitors, catheters, etc. which healthcare services are in constant need of. Good growth and demand even when everything else is weak. Have some concerns on foreign exchange and margin issues because of increase in costs of raw materials. Expecting about 10% earnings growth in 2009, which is a great earnings profile.
biotechnology/pharmaceutical
Brett Hryb

Vice President & Senior Portfolio Manager, MFC Global Investment Management

Price: $67.240
Owned: Yes

Showing 1 to 15 of 30 entries
<< < 1 2 > >>

No Comments.


You must be logged in to comment.